Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion

Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue to heat up.

For more details: Read More